Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study

Clinical and Experimental Allergy

Volumn 31, Issue 8, 2001, Pages 1295-1302

  Purello D'Ambrosio, F ^a   Gangemi, S ^a,c   Merendino, R A ^a   Isola, S ^a   Puccinelli, P ^b   Parmiani, S ^b   Ricciardi, L ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b ALK Abello SpA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Allergy; Monosensitization; Polysensitization; Prevention; Respiratory symptoms; Specific immunotherapy

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; POLLEN EXTRACT; STEROID;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRICK TEST; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RETROSPECTIVE STUDY; RHINITIS; SENSITIZATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; EPITOPES; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN E; ITALY; MALE; RECEPTORS, ADRENERGIC, BETA-2; RETROSPECTIVE STUDIES; RHINITIS;

EID: 0035726457     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01027.x     Document Type: Article

References (37)

1. Prophylactic inoculation against hay fever
2. WHO Position Paper. Allergen immunotherapy: Therapeutical vaccines for allergic diseases
3. Local Immunotherapy
4. Clinical efficacy of specific immunotherapy to cat dander: A double-blind placebo-controlled trial
5. Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy
6. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-Grass-pollen extract in rhinitis
7. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
8. Double-blind placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization
9. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo controlled study
10. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients
11. Sublingual immunotherapy: A double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both
12. Immunotherapy with partially purified and standardized tree pollen extract. IV. Results from long-term (6-year) follow-up
13. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen
14. Long-term clinical efficacy of grass-pollen immunotherapy
15. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of efficacy of immunotherapy after its cessation
16. The value of hyposensitization therapy for bronchial asthma in children - A 14-year study
17. The benefit of specific allergy treatment
18. Immunotherapy as a preventive treatment
19. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children
20. Intrinsic variability in airborne fungi: Implication for allergen standardization
21. Variazioni antigeniche nei ceppi e nei lotti di Alternaria isolati in Ann Arbor e in Napoli
22. The diagnosis of immediate-type allergy to Cladosporium herbarum. Differences between extracts and the efficacy of radioallergosorbent test (RAST) assay
23. Medical progress. Asthma in children; follow up study of 688 patients after an interval of 20 years
24. Longitudinal changes in allergen skin test reactivity in a community population sample
25. Long-term changes in inhalant allergy in asthmatic children
26. Predicting the course of asthma in children
27. Sensitization to airborne allergens in children with respiratory symptoms
28. Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children
29. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals
30. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis
31. 1 in T-cell clones specific for Phl, p. 1. A major grass pollen allergen
32. Immunologic mechanisms of specific immunotherapy
33. Differences in IL-4 release by PBMC are related with heterogeneity of atopy
34. Differences in clinical and immunological reactivity of patients allergic to grass pollens and to multiple species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts
35. Germinal center formation and local immunoglobulin E (IgE) production in the lung after an airway antigenic challenge
36. Specific immunotherapy prevents the onset of new sensitizations in monosensitized children
37. A controlled trial of immunotherapy for asthma in allergic children